HD1916 Semaglutide Trial: What Phase 3 Results Mean

Short answer: The HD1916 <a href="https://glp1place.com/tools/compound/semaglutide/”>semaglutide trial was a randomized phase 3 study in 462 Chinese adults with obesity but without diabetes. At week 44, average body-weight loss was 13.1% with chemically synthesized HD1916 and 14.4% with reference semaglutide. The difference was within the study’s prespecified therapeutic-equivalence margin. This is meaningful evidence for one defined follow-on semaglutide product, but it does not establish FDA approval, U.S. interchangeability, long-term equivalence, or the quality of unrelated semaglutide products.

The study was published online on October 7, 2026, in Diabetes, Obesity and Metabolism. Its findings are available through the study’s PubMed record. The trial compared HD1916 with reference semaglutide at 30 centers in China. HD1916 was developed by CSPC Baike, which funded the study, and several listed authors were affiliated with the sponsor. These disclosures do not determine whether the results are valid, but they matter when interpreting company-sponsored research.

The study addressed a narrow question: can a defined chemically synthesized semaglutide product produce body-weight results comparable with a selected reference product under a controlled phase 3 protocol? That is different from asking whether semaglutide works in general. It is also different from a regulatory finding that two products may be substituted for one another.

The trial measured body-weight change and reported broad safety findings over 44 weeks. It did not, by itself, settle questions about manufacturing consistency, impurities, stability, immune response, rare adverse events, years of treatment, or U.S. regulatory status. For a general framework, see GLP1Place’s guide to reading GLP-1 clinical trial data.

What the HD1916 semaglutide trial tested

HD1916 is a chemically synthesized form of semaglutide. Semaglutide is a glucagon-like peptide-1, or GLP-1, receptor agonist. GLP-1 medicines are studied and used in regulated settings for effects that include glucose regulation, appetite, gastric emptying, and food intake.

Rather than repeat the full clinical-development history of semaglutide, the study compared one defined HD1916 formulation with a reference semaglutide product. The key question was whether body-weight results in the two assigned groups stayed within a range set in advance by the protocol.

The trial enrolled adults aged 18 to 75 years with obesity, defined in the protocol as a body-mass index of at least 28 kilograms per square meter. Participants did not have diabetes. A total of 462 people were randomized in a 1:1 ratio: 231 received HD1916 and 231 received reference semaglutide.

Participants received assigned treatment once weekly by subcutaneous administration for 44 weeks. This describes the research protocol, not guidance for use. Trial registration details are available in the study’s ClinicalTrials.gov record.

The study was multicenter, active-controlled, randomized, and open-label. Randomization helps reduce systematic differences between groups at the start of a trial. Active-controlled means the comparison was with another semaglutide product rather than placebo. Open-label means participants and investigators knew which assigned product was used.

An open-label design does not automatically invalidate a study. Body weight is an objective measure, unlike a self-reported symptom. Still, knowing treatment assignment can affect behavior, symptom reporting, decisions to remain in a study, and discussion of adverse events. Weight results should therefore be considered alongside retention, detailed safety data, and other measures of comparability.

HD1916 semaglutide trial results at week 44

The primary endpoint was percentage change in body weight from baseline to week 44. Before analyzing the results, the investigators set a therapeutic-equivalence margin. To meet that criterion, the full 95% confidence interval for the difference between groups had to remain within plus or minus 4.16 percentage points.

At week 44, mean body weight had decreased by 13.1% in the HD1916 group and 14.4% in the reference semaglutide group. The estimated difference was 1.35 percentage points, with a 95% confidence interval from -0.02 to 2.72 percentage points. Because the full interval was inside the protocol’s range of -4.16 to 4.16 percentage points, the trial met its prespecified equivalence criterion.

This conclusion is specific. For this product, population, comparator, endpoint, and follow-up period, the observed difference in average body-weight change fell within the protocol’s planned margin. It does not mean the products are chemically identical in every respect. It also does not mean that every product described as chemically synthesized semaglutide would produce the same result.

The categorical weight-loss outcomes were also broadly similar. At least 5% weight loss was reported in 87.8% of participants assigned to HD1916 and 90.5% of those assigned to reference semaglutide. At least 10% weight loss was reported in 68.7% and 73.6%, respectively. Waist-circumference reductions were described as comparable.

Reported treatment-emergent adverse-event rates were 86.5% with HD1916 and 89.2% with reference semaglutide. Most events were described as grade 1 or 2. These overall percentages are useful, but they do not show that every adverse event, serious event, laboratory finding, treatment interruption, or discontinuation was the same between groups. Those questions require more detailed reporting.

What therapeutic equivalence means in this study

Therapeutic equivalence can have different meanings in different settings. In this paper, it refers to a statistical result defined in the study protocol. The researchers selected a margin of plus or minus 4.16 percentage points for the difference in percentage body-weight change, and the confidence interval around the observed difference stayed within that range.

A confidence interval describes uncertainty around an estimate. Here, the estimated difference was 1.35 percentage points, and the 95% confidence interval ran from -0.02 to 2.72 percentage points. Because neither end crossed the protocol boundary, the analysis met the planned criterion.

This does not prove there was zero difference. The point estimate was not zero, and a trial can meet an equivalence margin without showing that two products are identical. Instead, the finding means that the difference observed in this study was consistent with the pre-established range the protocol considered acceptable for that endpoint.

The size and clinical meaning of an equivalence margin remain important scientific questions. Researchers, regulators, and readers may consider whether a chosen margin is justified, whether it fits the endpoint, and whether other evidence supports the same conclusion. Body-weight change is important in an obesity study, but it is not the only evidence relevant to a complex peptide medicine.

The most accurate summary is therefore limited: HD1916 met the trial’s prespecified body-weight equivalence criterion against the selected reference semaglutide product. Broader claims require additional evidence.

Why chemical synthesis matters for semaglutide

Semaglutide is a complex peptide drug. Making a peptide medicine involves more than producing the intended amino-acid sequence. The finished product must be made consistently, carefully characterized, and assessed for substances that may arise during synthesis, purification, formulation, filling, transport, or storage.

Chemical synthesis can assemble peptide molecules through controlled reactions. Other peptide medicines may be produced through recombinant or semi-synthetic approaches. Different production routes may produce the intended molecule, but a matching sequence alone does not establish that finished products have the same impurity profile, higher-order behavior, biological activity, stability, or clinical performance.

Impurities can include altered or incomplete peptide molecules, degradation products, aggregates, or other substances. Their importance depends on identity, amount, behavior over time, and biological effects. A stated purity percentage alone cannot provide a complete picture of a medicine’s quality, stability, potency, or clinical performance.

The HD1916 result is more informative than a claim based only on a chemistry description or one purity figure. It provides clinical evidence from a controlled study of one defined product. However, it does not remove the need for chemistry, manufacturing, and controls evidence.

The FDA has discussed these issues in revised draft product-specific guidance for certain generic peptide products. The agency identifies topics that may include impurity thresholds, higher-order structure, biological activity, and innate immune-response testing. This helps explain why a clinical body-weight endpoint can be important while remaining only one part of a broader product assessment. See the FDA’s announcement on revised draft guidance for certain generic peptide products.

Why the finding does not establish FDA approval

The HD1916 study was conducted in China and reports a clinical trial result. It does not announce or establish FDA approval in the United States. FDA approval is product-specific and requires an application, agency review, and an FDA determination.

Depending on the regulatory pathway, review can include manufacturing controls, identity and purity, stability, pharmacology, toxicology, clinical pharmacokinetics, immunogenicity, efficacy, safety, labeling, and manufacturing facilities. A positive clinical endpoint from one study does not automatically answer all of those questions.

Likewise, the study’s use of therapeutic equivalence does not establish U.S. therapeutic interchangeability. FDA’s Orange Book is the agency’s resource for approved drug products with therapeutic-equivalence evaluations; a clinical-trial conclusion is not itself an Orange Book determination. The FDA explains these evaluations in its Orange Book overview.

The result also does not authorize compounding or validate unrelated products. FDA has cautioned that unapproved GLP-1 products do not undergo the same premarket review for safety, effectiveness, and quality as approved medicines. Its discussion of unapproved GLP-1 drugs used for weight loss describes concerns that can include dosing errors, fraudulent labeling, and semaglutide salt forms that are not the active ingredient in approved semaglutide products.

For background on the distinction between investigational materials and regulated medicines, see GLP1Place’s article on research peptides versus pharmaceutical compounds. A product name, chemical claim, or document describing a batch is not a substitute for product-specific regulatory review.

What remains unknown about immune response and long-term safety

Immunogenicity is the ability of a drug to prompt an unwanted immune response. For peptide medicines, evaluation can include anti-drug antibodies, neutralizing activity, immune-cell activation, and whether immune responses affect drug exposure, efficacy, or safety.

The HD1916 trial is listed in ClinicalTrials.gov, and the registry includes information beyond the headline body-weight result. However, the reported primary results summarized here do not by themselves settle detailed questions about anti-drug antibody incidence, antibody levels, neutralizing activity, or how immune findings may relate to clinical outcomes. Those are separate evidence questions.

A body-weight outcome is not a complete assessment of immune response. A product could meet a prespecified weight-loss margin while still requiring careful review of analytical comparability, stability, immune response, rare adverse events, and longer-term outcomes.

The 44-week duration is substantial for an obesity study and allowed the researchers to observe a large average weight-loss response. It does not establish years of comparative safety, long-term weight maintenance, or the frequency of rare events that may require larger or longer datasets.

Laboratory research on tested follow-on and compounded semaglutide and liraglutide products has reported impurity-profile differences from originator products. The work used methods including liquid chromatography-mass spectrometry, peptide-presentation assays, photostability testing, and fibrillation assays. This research reinforces why impurities and possible immune recognition require product-specific evaluation. The researchers were affiliated with Novo Nordisk, so the findings should be considered alongside independent evidence and regulatory assessment. The publication is indexed at PubMed.

A Certificate of Analysis is not clinical evidence. It may report batch identity or a purity measurement, but it cannot establish long-term clinical safety, sterility throughout distribution, immune effects, dose consistency, or therapeutic equivalence. GLP1Place’s guide to peptide quality testing explains why purity is only one part of quality assessment.

How strong is the HD1916 evidence?

The study has several strengths. It was randomized, multicenter, active-controlled, and designed with a prespecified equivalence margin. It enrolled 462 participants, followed treatment for 44 weeks, and compared HD1916 directly with reference semaglutide instead of comparing separate studies with different populations and protocols.

It also examined a clinically meaningful endpoint: percentage body-weight change. This endpoint is easy to understand, objectively measured, and directly relevant to the population enrolled.

Its limitations define the boundaries of the result:

• Open-label design: Knowing the assigned treatment can affect behavior, symptom reporting, and study continuation.
• Population limits: Participants were Chinese adults with obesity without diabetes. Results may not transfer directly to people with diabetes or other populations.
• Duration: Forty-four weeks cannot answer all questions about years of treatment, maintenance, or rare adverse events.
• Sponsor involvement: CSPC Baike funded the study and several authors were affiliated with the sponsor.
• Endpoint scope: The equivalence conclusion applies to the planned body-weight endpoint, not automatically to every quality, safety, or regulatory question.
• No U.S. regulatory conclusion: The trial does not establish FDA approval, substitution status, or authorization for compounding.

These limitations do not erase the result. They show how it should be used: as evidence about one defined HD1916 product under one phase 3 protocol. The study cannot independently settle every question about broader manufacturing comparability or long-term use.

What the result could mean for follow-on GLP-1 development

The HD1916 program shows that follow-on peptide development can move beyond theoretical claims toward product-specific clinical testing. This study examined a defined formulation, made through a defined process, in a defined population, against a defined comparator.

That approach is more informative than general claims about a molecule’s name or manufacturing route. It creates a record that readers can assess for protocol design, effect size, confidence intervals, population, duration, and reported safety findings.

If later evidence and regulatory review support the program, chemically synthesized semaglutide may become part of a broader follow-on GLP-1 development landscape. Possible implications could include more experience evaluating complex peptide products and additional manufacturing capacity. These outcomes are not automatic. They depend on the complete evidence package and regulatory decisions, not one positive body-weight study.

The trial may also prompt discussion about equivalence margins. Here, the 1.35-percentage-point estimated difference and its confidence interval fit within the protocol’s plus-or-minus 4.16-point margin. Researchers and regulators can still consider whether the margin is clinically suitable and whether analytical, safety, and immunogenicity data support the same conclusion.

Most importantly, the HD1916 study should not be used to validate unrelated products. It tested one sponsor’s defined product under controlled research conditions. It cannot establish the identity, quality, safety, or performance of unrelated powders, vials, compounded preparations, or imported products. For related context, GLP1Place’s coverage of compounded GLP-1 impurities explains why manufacturing route and impurity profiles remain relevant.

Bottom line

The October 7, 2026 HD1916 semaglutide trial is a meaningful phase 3 development. It provides direct clinical evidence that one chemically synthesized semaglutide product met a prespecified body-weight equivalence criterion against reference semaglutide in adults with obesity but without diabetes.

At week 44, average body-weight loss was 13.1% with HD1916 and 14.4% with reference semaglutide. The estimated difference was 1.35 percentage points, and the 95% confidence interval remained within the protocol’s equivalence margin.

The appropriate interpretation is specific rather than broad. One defined HD1916 product passed one defined phase 3 body-weight comparison in one study population. The result supports continued research into follow-on peptide products. It does not prove that all chemically synthesized semaglutide is equivalent, establish FDA approval or interchangeability, or replace evidence on manufacturing controls, impurities, immune response, stability, and long-term safety.

Frequently asked questions

What is HD1916?

HD1916 is a chemically synthesized semaglutide injection developed by CSPC Baike and studied as a follow-on product to reference semaglutide. A phase 3 result does not mean HD1916 is FDA approved or interchangeable with Wegovy in the United States.

What did the HD1916 semaglutide trial find?

At week 44, average body weight decreased by 13.1% with HD1916 and 14.4% with reference semaglutide. The estimated difference was 1.35 percentage points, with a 95% confidence interval from -0.02 to 2.72, inside the study’s prespecified equivalence margin of plus or minus 4.16 percentage points.

Was the HD1916 trial randomized?

Yes. The multicenter, open-label phase 3 trial randomized 462 adults with obesity but without diabetes in a 1:1 ratio to HD1916 or reference semaglutide. It was conducted at 30 centers in China and evaluated the primary endpoint at week 44.

Is HD1916 approved by the FDA?

The published trial does not establish FDA approval. A clinical equivalence finding in China is not the same as U.S. approval, therapeutic interchangeability, or authorization for compounding.

Does the trial prove all chemically synthesized semaglutide is equivalent to Wegovy?

No. The findings apply only to the tested HD1916 product, manufacturing process, formulation, schedule, study population, and trial conditions. They cannot be generalized to every chemically synthesized, compounded, or unapproved semaglutide product.

Why do impurities and immunogenicity matter for follow-on semaglutide?

Peptide impurities can include altered or incomplete molecules, degradation products, aggregates, or other substances generated during synthesis and storage. These differences may affect potency, stability, or immune recognition, so follow-on peptide products need detailed analytical and immunogenicity evaluation.